pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
Gene Therapy (AAV) · news · pharmadog
← back to Gene Therapy (AAV)
News · Gene Therapy (AAV)
527
stories
Sep 10, 26
STAT+: FDA expands Bayer lung cancer drug approval
stat
Sep 10, 26
Encoded raises $275M series F for Dravet syndrome gene therapy
biospace
Sep 10, 26
The supply chain fault lines of modern pharma
biospace
Sep 10, 26
STAT+: Roivant is one of the savviest dealmakers in biotech. It also has a secret weapon
stat
Sep 10, 26
STAT+: What to expect from UniQure’s upcoming Huntington’s gene therapy readout
stat
Sep 9, 26
STAT+: Pharmalittle: We’re reading about an AstraZeneca COPD win, the FDA filling key jobs, and more
stat
Sep 9, 26
Novo’s canned heart disease trials, Novartis’ clinical fails, first approval for Alexander disease
biospace
Sep 9, 26
GV-backed Encoded gains $275M to advance Dravet drug, scale genetic med manufacturing
fiercebiotech
Sep 8, 26
STAT+: FDA warns an API supplier about residue on walls, a corroded product line, and open-toed sandals
stat
Sep 8, 26
STAT+: Pharmalittle: We’re reading about another Novartis trial failure, a Novo Nordisk setback, and more
stat
Sep 8, 26
Diabetes cell therapy biotechs Sernova and Seraxis to merge
endpoints
Sep 8, 26
BrainChild hauls in $116M to make cell therapies for childhood brain cancers
biopharma dive
Sep 8, 26
Bristol Myers’ pivotal CAR-T multiple myeloma trial hits primary endpoint
fiercebiotech
Sep 8, 26
#ERS26: Beam says AATD base editing data hold up after one year
endpoints
Sep 4, 26
This week in charts: China deals, stock flatlines and Lilly’s M&A spree
biopharma dive
Sep 4, 26
10 life sciences startups selected for accelerator program
biospace
Sep 4, 26
STAT+: We’re reading about a Bristol CAR-T trial pause, Pfizer offloading a shelved candidate, and more
stat
Sep 3, 26
Ultragenyx to weigh ‘significant’ cost cuts as Angelman drug fails key study
biopharma dive
Sep 3, 26
STAT+: We’re reading about an Ultragenyx failure, RevMed for lung cancer, and more
stat
Sep 3, 26
The hidden scale-out problem behind CAR-T’s growth
biopharma dive
Sep 3, 26
Ultragenyx’s 'high-risk' Angelman bet fails, cratering stock and forcing strategic review
biospace
Sep 3, 26
Capricor, Replimune illustrate why FDA must listen to rare disease specialists
biospace
Sep 3, 26
Ultragenyx fails phase 3 Angelman test, plots ‘significant expense reductions’
fiercebiotech
Sep 3, 26
Industry asks FDA to expand prior knowledge guidance
raps
Sep 2, 26
FDA raises bar for foreign site inspections as China trials surge
biospace
Sep 2, 26
Autoimmune CAR-T faces tough questions after Novartis, Bristol Myers study halts
biopharma dive
Sep 2, 26
UniQure, after setbacks, seeks FDA approval of Huntington’s gene therapy
biopharma dive
Sep 2, 26
UK regulator halts sales of Tavneos; UniQure seeks approval for Huntington's gene therapy
endpoints
Sep 2, 26
Doctors groups release vaccination guidelines ahead of respiratory illness season
stat
Sep 2, 26
STAT+: ARPA-H funds biotechs working on custom RNA therapies
stat
← prev
page 9 of 18
next →